IGFBP-2 inhibits adipogenesis and lipogenesis in human visceral, but not subcutaneous, adipocytes

International Journal of Obesity

Volumn 39, Issue 5, 2015, Pages 770-781

  Yau, S W ^a,b,c   Russo, V C ^a,b   Clarke, I J ^c   Dunshea, F R ^d   Werther, G A ^a,b   Sabin, M A ^a,b,c  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CCAAT ENHANCER BINDING PROTEIN ALPHA; ECHISTATIN; FOCAL ADHESION KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SMALL INTERFERING RNA; SOMATOMEDIN BINDING PROTEIN 2; ANTITHROMBOCYTIC AGENT; PEPTIDE; SOMATOMEDIN C;

ADIPOCYTE; ADIPOGENESIS; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CELL SURFACE; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRAABDOMINAL FAT; LIPOGENESIS; PRIORITY JOURNAL; PROADIPOCYTE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA ANALYSIS; SIGNAL TRANSDUCTION; SUBCUTANEOUS ADIPOCYTE; SUBCUTANEOUS FAT; VISCERAL ADIPOCYTE; ANIMAL; CELL CULTURE; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PHOSPHORYLATION; TRANSGENIC MOUSE;

MUS MUSCULUS;

ADIPOCYTES; ADIPOGENESIS; ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; GENE EXPRESSION REGULATION; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR I; INTRA-ABDOMINAL FAT; LIPOGENESIS; MICE; MICE, TRANSGENIC; PEPTIDES; PHOSPHORYLATION; PLATELET AGGREGATION INHIBITORS;

EID: 84928925346     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2014.192     Document Type: Article

References (45)

1. Swinburn BA, Sacks G, Hall KD, McPherson K, Finegood DT, Moodie ML et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet 2011; 378: 804-814.
2. Tataranni PA, Ravussin E. Effect of fat intake on energy balance. Ann NY Acad Sci 1997; 819: 37-43.
3. Arner E, Westermark PO, Spalding KL, Britton T, Rydén M, Frisén J et al. Adipocyte turnover: relevance to human adipose tissue morphology. Diabetes 2010; 59: 105-109.
4. Spalding KL, Arner E, Westermark PO, Bernard S, Buchholz BA, Bergmann O et al. Dynamics of fat cell turnover in humans. Nature 2008; 453: 783-787.
5. Spiegelman BM, Flier JS. Adipogenesis and obesity: rounding out the big picture. Cell 1996; 87: 377-389.
6. Attie AD, Scherer PE. Adipocyte metabolism and obesity. J Lipid Res 2009; 50: S395-S399.
7. Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 2008; 9: 367-377.
8. Larsson B. Obesity, fat distribution and cardiovascular disease. Int J Obes 1991; 15: 53-57.
9. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000; 21: 697-738.
10. Ibrahim MM. Subcutaneous and visceral adipose tissue: Structural and functional differences. Obes Rev 2010; 11: 11-18.
11. Brun RP, Kim JB, Hu E, Altiok S, Spiegelman BM. Adipocyte differentiation: a transcriptional regulatory cascade. Curr Opin Cell Biol 1996; 8: 826-832.
12. Gregoire F, Smas C, Sul H. Understanding adipocyte differentiation. Physiol Rev 1998; 78: 783-809.
13. Cristancho A, Lazar M. Forming functional fat: a growing understanding of adipocyte differentiation. Nat Rev Mol Cell Biol 2011; 28: 722-734.
14. Smith PJ, Wise LS, Berkowitz R, Wan C, Rubin CS. Insulin-like growth factor-I is an essential regulator of the differentiation of 3T3-L1 adipocytes. J Biol Chem 1988; 263: 9402-9408.
15. Russo VC, Gluckman PD, Feldman EL, Werther GA. The insulin-like growth factor system and its pleiotropic functions in brain. Endocr Rev 2005; 26: 916-943.
16. Boney CM, Moats-Staats BM, Stiles AD, D'Ercole AJ. Expression of insulin-like growth factor-I (IGF-I) and IGF-binding proteins during adipogenesis. Endocrinology 1994; 135: 1863-1868.
17. Bhala A, Harris M, Zirin S, Corcoran L, Cohen P. Insulin-like growth factor axis parameters in sick hospitalized neonates. J Pediatr Endocrinol Metab 1998; 11: 451-459.
18. Sabin MA, Russo VC, Azar WJ, Yau SW, Kiess W, Werther GA. IGFBP-2 at the interface of growth and metabolism-implications for childhood obesity. Pediatr Endocrinol Rev 2011; 8: 382-393.
19. Sabin MA, Yau SW, Russo VC, Clarke IJ, Dunshea FR, Chau J et al. Dietary monounsaturated fat in early life regulates IGFBP2: implications for fat mass accretion and insulin sensitivity. Obesity 2011; 19: 2374-2381.
20. Nam S, Lee E, Kim K, Cha B, Song Y, Lim S. Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone. Int J Obes Relat Metab Disord 1997; 21: 355-359.
21. Ballerini MG, Ropelato MG, Domene HM, Pennisi P, Heinrich JJ, Jasper HG. Differential impact of simple childhood obesity on the components of the growth hormone-insulin-like growth factor (IGF)-IGF binding proteins axis. J Pediatr Endocrinol Metab 2004; 17: 749-757.
22. Claudio M, Benjamim F, Riccardo B, Massimiliano C, Francesco B, Luciano C. Adipocytes IGFBP-2 expression in prepubertal obese children. Obesity 2010; 18: 2055-2057.
23. Li Z, Picard F. Modulation of IGFBP2 mRNA expression in white adipose tissue upon aging and obesity. Horm Metab Res 2010; 787-791.
24. Wheatcroft S, Kearney M, Shah A, Ezzat V, Miell J, Modo M. IGF-binding protein-2 protects against the development of obesity and insulin resistance. Diabetes 2007; 56: 284-294.
25. Russo VC, Schütt BS, Andaloro E, Ymer SI, Hoeflich A, Ranke MB et al. Insulin-like growth factor binding protein-2 binding to extracellular matrix plays a critical role in neuroblastoma cell proliferation, migration, and invasion. Endocrinology 2005; 146: 4445-4455.
26. Russo VC, Bach LA, Fosang AJ, Baker NL, Werther GA. Insulin-like growth factor binding protein-2 binds to cell surface proteoglycans in the rat brain olfactory bulb. Endocrinology 1997; 138: 4858-4867.
27. Shen X, Xi G, Maile LA, Wai C, Rosen CJ, Clemmons DR. Insulin-like growth factor (IGF) binding protein 2 functions coordinately with receptor protein tyrosine phosphatase ? and the IGF-I receptor to regulate IGF-I-stimulated signaling. Mol Cell Biol 2012; 32: 4116-4130.
28. Schutt B, Langkamp M, Rauschnabel U, Ranke M, Elmlinger M. Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. J Mol Endocrinol 2004; 32: 859-868.
29. Wheatcroft SB, Kearney MT. IGF-dependent and IGF-independent actions of IGF-binding protein-1 and-2: implications for metabolic homeostasis. Trends Endocrinol Metab 2009; 20: 153-162.
30. Xi G, Solum MA, Wai C, Maile LA, Rosen CJ, Clemmons DR. The heparinbinding domains of IGFBP-2 mediate its inhibitory effect on preadipocyte differentiation and fat development in male mice. Endocrinology 2013; 154: 4146-4157.
31. Yau SW, Henry BA, Russo VC, McConell GK, Clarke IJ, Werther GA et al. Leptin enhances insulin sensitivity by direct and sympathetic nervous system regulation of muscle IGFBP-2 expression: evidence from nonrodent models. Endocrinology 2014; 155: 2133-2143.
32. Hu ED, Kim JB, Sarraf P, Spiegelman BM. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPAR gamma. Science 1996; 274: 2100-2103.
33. Smas CM, Sul HS. Pref-1 a protein containing EGF-like repeats, inhibits adipocyte differentiation. Cell 1993; 73: 725-734.
34. Kovacova Z, Tencerova M, Roussel B, Wedellova Z, Rossmeislova L, Langin D et al. The impact of obesity on secretion of adiponectin multimeric isoforms differs in visceral and subcutaneous adipose tissue. Int J Obes 2012; 36: 1360-1365.
35. Sabin MA, Crowne EC, Stewart CE, Hunt LP, Turner SJ, Welsh GI et al. Depot-specific effects of fatty acids on lipid accumulation in children's adipocytes. Biochem Biophys Res Commun 2007; 361: 356-361.
36. Einstein FH, Atzmon G, Yang XM, Ma XH, Rincon M, Rudin E et al. Differential responses of visceral and subcutaneous fat depots to nutrients. Diabetes 2005; 54: 672-678.
37. Lihn AS, Bruun JM, He GS, Pedersen SB, Jensen PF, Richelsen B. Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol Cell Endocrinol 2004; 219: 9-15.
38. Holly JMP, Sabin MA, Perks CM, Shield JP. Adipogenesis and IGF-1. Metab Syndr Relat Disord 2006; 4: 43-50.
39. Kuang Z, Yao S, Keizer DW, Wang CC, Bach LA, Forbes BE et al. Structure, dynamics and heparin binding of the C-terminal domain of insulin-like growth factorbinding protein-2 (IGFBP-2). J Mol Biol 2006; 364: 690-704.
40. Lin YT, Tang C. H, Chuang WJ, Wang SM, Huang TF, Fu WM. Inhibition of adipogenesis by RGD-dependent disintegrin. Biochem Pharmacol 2005; 70: 1469-1478.
41. Liu J, DeYoung SM, Zhang M, Zhang M, Cheng A, Saltiel AR. Changes in integrin expression during adipocyte differentiation. Cell Metab 2005; 2: 165-177.
42. Bretscher MS. Circulating integrins: alpha 5 beta 1, alpha 6 beta 4 and Mac-1, but not alpha 3 beta 1, alpha 4 beta 1 or LFA-1. EMBO J 1992; 11: 405-410.
43. Caswell PT, Norman JC. Integrin trafficking and the control of cell migration. Traffic 2006; 7: 14-21.
44. Wang Y, Zhao L, Smas C, Sul HS. Pref-1 interacts with fibronectin to inhibit adipocyte differentiation. Mol Cell Biol 2010; 30: 3480-3492.
45. Luk CT, Shi SY, Cai EP, Sivasubramaniyam T, Schroer SA, Woo M. Adipocytespecific FAK deletion in mice leads to insulin resistance but divergent adipose tissue remodelling under lean and obese conditions. Can J Diabetes 2013; 37: 433-434.